vTv Therapeutics Inc (NASDAQ:VTVT) Expected to Post Quarterly Sales of $1.26 Million

Wall Street brokerages expect vTv Therapeutics Inc (NASDAQ:VTVT) to post $1.26 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for vTv Therapeutics’ earnings, with the highest sales estimate coming in at $2.50 million and the lowest estimate coming in at $10,000.00. vTv Therapeutics reported sales of $4.52 million in the same quarter last year, which indicates a negative year-over-year growth rate of 72.1%. The company is scheduled to report its next earnings report on Wednesday, February 26th.

According to Zacks, analysts expect that vTv Therapeutics will report full-year sales of $5.24 million for the current financial year, with estimates ranging from $2.77 million to $7.70 million. For the next fiscal year, analysts expect that the business will post sales of $6.38 million, with estimates ranging from $2.75 million to $10.00 million. Zacks’ sales averages are an average based on a survey of research firms that follow vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $1.69 million.

Several equities analysts have issued reports on VTVT shares. Zacks Investment Research upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research note on Friday, November 8th. ValuEngine upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Northland Securities reiterated a “buy” rating on shares of vTv Therapeutics in a research note on Thursday, October 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of vTv Therapeutics in a research note on Friday, August 16th.

In related news, major shareholder Ronald O. Perelman bought 50,000 shares of the company’s stock in a transaction on Thursday, August 22nd. The stock was bought at an average cost of $1.38 per share, with a total value of $69,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ronald O. Perelman bought 1,369,863 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was bought at an average cost of $1.46 per share, with a total value of $1,999,999.98. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 4,770,650 shares of company stock valued at $7,077,251. 1.70% of the stock is currently owned by corporate insiders.

A hedge fund recently bought a new stake in vTv Therapeutics stock. Wedbush Securities Inc. bought a new stake in vTv Therapeutics Inc (NASDAQ:VTVT) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 25,100 shares of the biotechnology company’s stock, valued at approximately $39,000. 6.12% of the stock is currently owned by institutional investors.

NASDAQ VTVT traded up $0.02 during trading hours on Friday, hitting $1.55. The company had a trading volume of 58,306 shares, compared to its average volume of 708,035. vTv Therapeutics has a 1-year low of $1.00 and a 1-year high of $3.50. The company has a market cap of $84.99 million, a PE ratio of -2.25 and a beta of -3.61. The business has a 50 day moving average of $1.47 and a 200-day moving average of $1.46.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

Read More: What is the 52-week high/low?

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.